Dexmedetomidine Infusion in Either Total Intravenous Anesthesia or Inhalational Anesthesia to Improve Surgical Field Visibility in Endoscopic Sinus Surgery

NCT ID: NCT06866145

Last Updated: 2025-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2025-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dexmedetomidine Infusion in either Total Intravenous Anesthesia or Inhalational Anesthesia to Improve Surgical Field Visibility in Endoscopic Sinus Surgery

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

the study was prospective randomized single blinded study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinosinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

surgeon

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TIVA group

patients receives total intravenous anesthesia

Group Type OTHER

functional endoscopic sinus surgery

Intervention Type PROCEDURE

sinus surgery

Dexmedetomidine

Intervention Type DRUG

precedex

inhalational group

patients receives inhalational anesthesia

Group Type OTHER

functional endoscopic sinus surgery

Intervention Type PROCEDURE

sinus surgery

Dexmedetomidine

Intervention Type DRUG

precedex

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

functional endoscopic sinus surgery

sinus surgery

Intervention Type PROCEDURE

Dexmedetomidine

precedex

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists (ASA) class I and II patients undergoing endoscopic sinus surgery in the age group from 18-50 years.

Exclusion Criteria

* History of allergy to medications used in the study, refusal of patients to participate, hepatic or renal dysfunction, chronic pain condition, psychological and neurological disorders
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Menoufia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Menoufia university hospital

Menoufia, Shibin Elkom, Egypt

Site Status

Menoufia university hospital

Shibin Elkom, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3/2024 ANE T8

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Functional Endoscopic Sinus Surgery Study
NCT03970655 RECRUITING PHASE1/PHASE2
Topical Irrigation Therapy for CRS
NCT02630472 TERMINATED PHASE1/PHASE2